

PATENT 1199-1-001 CIPA

NTHE UNITED STATES PATENT AND TRADEMARK OFFICE

**APPLICANTS:** 

Moses Rodriguez, et al.

SERIAL NO.:

08/692,084

**EXAMINER:** 

P. Duffy

**FILED** 

August 8, 1996

ART UNIT

1640

FOR

MONOCLONAL ANTIBODIES WHICH PROMOTE CENTRAL

NERVOUS SYSTEM REMYELINATION

## **CERTIFICATE OF MAILING UNDER 37 CFR 1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231

on March 1, 1999.

<u>David A. Jackson, Reg. No. 26,742</u> (Name of Registered Representative) <u>SUN DAILY 3</u>/1/9 9 (Signature and Date)

## **AMENDMENT UNDER 37 CFR 1.116**

ASSISTANT COMMISSIONER FOR PATENTS BOX AF WASHINGTON, D.C. 20231

Dear Sir:

This Amendment is submitted in Response to the Office Action dated September 1, 1998, issued by the United States Patent and Trademark Office in connection with the above-identified application. A response to the September 1, 1998 Office Action is due December 1, 1998. Applicants are concurrently submitting herewith a Petition for a Three-Month Extension of Time including the required fee. Therefore a response is due March 1, 1999. Accordingly, this Amendment is being timely filed. Please consider the following Amendment and remarks for purposes of allowance, or in the alternative, to narrow the issues on appeal.

## **IN THE SPECIFICATION:**

On page 2, line 20 please replace "The monoclonal antibodies referred to as SCH94.03 and SCH 79.03 and the corresponding hybridomas producing them have been

De walk